Skip to content
OpenCapital
Get started

Bio-Rad Laboratories, Inc. BIO.B Equity Securities Without Readily Determinable Fair Value - Cumulative Downward Adjustments

Equity Securities Without Readily Determinable Fair Value - Cumulative Downward Adjustments at other companies

Agilent Technologies logo
Agilent TechnologiesA
——
Bruker logo
BrukerBRKR
——
Illumina logo
IlluminaILMN
——

Other financials

Income statement

See full
Revenue$592.1M+1.1%
Gross profit$309.4M+1.1%
Operating income$34.1M+43.9%
Net income-$527.1M-924%
EPS (diluted)-$19.55-954%

Balance sheet

See full
Cash & equivalents$509.0M-2.7%
Total debt$987.3M-28.4%
Total equity$6.9B+2.6%
Total assets$9.8B+2.8%

Cash flow

See full
Operating cash flow$108.1M-16.8%
CapEx$30.0M-12.8%
Free cash flow$78.1M-18.2%

Valuation

See full
Market cap$7.56B+10.3%
Enterprise value$8.04B+4.2%
P/E44.8×—
P/S2.9×+0.2×

Profitability

See full
Gross margin51.9%-1.6pp
Operating margin8.8%-3.1pp
Net margin6.5%+3.4pp
FCF margin13.8%-0.2pp

Returns & leverage

See full
Return on equity2.5%+1.3pp
Debt / equity0.1×-0.1×
Current ratio3.2×-2.8×

Where this comes from

Reported directly by Bio-Rad Laboratories, Inc. in its filing.

Tagged under the XBRL concept us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount.

The official record: Bio-Rad Laboratories, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bio-Rad Laboratories, Inc.'s equity securities without readily determinable fair value - cumulative downward adjustments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bio-Rad Laboratories, Inc.'s equity securities without readily determinable fair value - cumulative downward adjustments?
Bio-Rad Laboratories, Inc. (BIO.B) reported equity securities without readily determinable fair value - cumulative downward adjustments of $23.7M in Q1 2026.
How has Bio-Rad Laboratories, Inc.'s equity securities without readily determinable fair value - cumulative downward adjustments changed year-over-year?
Bio-Rad Laboratories, Inc.'s equity securities without readily determinable fair value - cumulative downward adjustments increased by 3.0% year-over-year, from $23M to $23.7M.
What is the long-term trend for Bio-Rad Laboratories, Inc.'s equity securities without readily determinable fair value - cumulative downward adjustments?
Over 2 years (2020 to 2025), Bio-Rad Laboratories, Inc.'s equity securities without readily determinable fair value - cumulative downward adjustments has grown at a 578.2% compound annual growth rate (CAGR), from $500K to $23M.